UHealth - University of Miami Health System

E-mail a Friend


Michael Benatar, M.D., Ph.D.

General Information

Michael  Benatar, M.D., Ph.D.

Contact:

Specialties

  • Neuromuscular Medicine - Psych & Neuro
  • Neurology (Psychiatry & Neurology)
  • Neurophysiology, Clinical - Psych & Neuro

Languages

English

Clinical Areas

ALS and myasthenia gravis

Certifications

  • Neurology (American Board of Psychiatry & Neurology)

Roles

  • Chief, Neuromuscular Division
  • Professor of Neurology

Research Interests

 

Dr. Benatar has a well-developed research program specializing in Amyotrophic Lateral Sclerosis (ALS) and Myasthenia Gravis (MG). Please see the link below for information about some of his current and past research studies as well as publications.
 

 

Education

2005 MS
Emory University
2003 Fellowship
Beth Israel Deaconess Medical Center
2002 Residency
Beth Israel Deaconess Medical Center
1998 DPhil
Oxford
1992 MBChB
University of Cape Town

Biography

Dr. Michael Benatar is a Professor of Neurology and of Public Health Sciences, and Chief of Neuromuscular Division at the University of Miami where he also holds the Walter Bradley Chair in ALS Research. He obtained his medical degree at the University of Cape Town in South Africa and is also trained in both basic neuroscience (DPhil, Oxford) and clinical research methods (Masters in the Science of Clinical Research Emory). He directs an active clinical and translational research program focused on therapy development for myasthenia gravis as well as ALS biomarker and therapy development funded by the NIH, FDA, CDC, DOD, MDA and the ALS Association. He is the principal investigator of the Clinical Research in ALS and related disorder for Therapeutic development (CReATe), an NIH-funded Rare Diseases Clinical Research Consortium focused on phenotype-genotype relationships in ALS and related disorders as well as biomarker development. He is also the principal investigator of the Pre-symptomatic familial ALS (Pre-fALS) study, a systematic and longitudinal biomarker study of people at genetic risk for developing ALS.

 

E-mail a Friend